Stocktoria
Ovid Therapeutics Inc. OVID
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-05-05
Ovid Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2025 | FY2024 | FY2024 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $7.3M | $223.6M | $566,000 | $223.4M | $223.2M |
| R&D expense | $25.6M | — | $36.8M | — | — |
| Operating income | -$42.4M | — | -$61.9M | — | — |
| Income tax | $0 | — | $0 | — | — |
| Net income | -$17.4M | — | -$26.4M | — | — |
| Operating cash flow | -$38.3M | — | -$56.0M | — | — |
| Free cash flow | -$38.3M | — | -$56.0M | — | — |
| Cash & equivalents | $13.2M | $21.1M | $26.3M | $15.0M | $29.7M |
| Total assets | $150.9M | $81.7M | $92.2M | $102.7M | $118.1M |
| Total liabilities | $20.3M | $22.4M | $23.9M | $26.4M | $29.2M |
| Shareholders' equity | $130.7M | $59.3M | $68.2M | $76.3M | $88.9M |
Source: SEC EDGAR filings · CIK 0001636651 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.